Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or establish its own sales force.

The funds will push the company's two lead candidates through to registration, Philogen S.p.A. (Siena, Italy) co-founder Dario Neri told BioCentury. Both

Read the full 610 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE